You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Papaverine

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Papaverine?

Papaverine is an investigational drug.

There have been 16 clinical trials for Papaverine. The most recent clinical trial was a Phase 3 trial, which was initiated on May 15th 2017.

The most common disease conditions in clinical trials are Erectile Dysfunction, Enuresis, and Pancreatic Diseases. The leading clinical trial sponsors are Cairo University, National Cancer Institute (NCI), and University of Nebraska.

There are two US patents protecting this investigational drug and twenty-two international patents.

Recent Clinical Trials for Papaverine
Effect of Papaverine on Renal Artery Blood Flow VolumeAsan Medical CenterPhase 4
Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric PatientsThe University of Texas Health Science Center, HoustonPhase 4
Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With EDBenha UniversityPhase 2/Phase 3

See all Papaverine clinical trials

Clinical Trial Summary for Papaverine

Top disease conditions for Papaverine
Top clinical trial sponsors for Papaverine

See all Papaverine clinical trials

US Patents for Papaverine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Papaverine   Start Trial Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)   Start Trial
Papaverine   Start Trial Cytochrome P450 fusion protein The University of York (York, GB) Sun Pharmaceutical Industries (Australia) Pty Ltd (Notting Hill, Victoria, AU)   Start Trial
Papaverine   Start Trial Matrix and layer compositions for protection of bioactives Novus International, Inc. (St. Charles, MO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Papaverine

Drugname Country Document Number Estimated Expiration Related US Patent
Papaverine World Intellectual Property Organization (WIPO) 2014052836 2032-09-27   Start Trial
Papaverine Australia 2015261278 2034-05-16   Start Trial
Papaverine Australia 2019253858 2034-05-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.